The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly

Helen E. Baxendale; Sheila M. Keating; Marina Johnson; Jo Southern; Elizabeth Miller; David Goldblatt

doi:10.1016/j.vaccine.2010.04.103

The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly

Helen E. Baxendale^*, Sheila M. Keating, Marina Johnson, Jo Southern, Elizabeth Miller, David Goldblatt

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

41 Citations (Scopus)

Abstract

In young children, polyvalent pneumococcal polysaccharide conjugate vaccines (PCVs) have been shown to offer advantage over plain polysaccharide vaccines (PPVs) in both immunogenicity and priming for memory responses. In the elderly, the potential benefit of conjugate vaccines is unclear.Here, we explore the early kinetics of serum antibody and circulating plasma and memory B cell responses to pneumococcal capsular polysaccharide (PPS) in older adults (n=37) immunised a PPV vaccine, Pneumovax™ or a PCV: Prevenar™. All individuals had serum evidence of pre-existing serotype-specific immunity. Following immunisation, a day 7 rise in circulating PPS-specific plasma and memory antibody secreting cells (AbSCs) was detected in both vaccine groups and this was sustained to day 28 in some PCV recipients. There was no difference between vaccine groups in serum antibody responses or the kinetics of the early PBMC-derived B cell responses. Although our sample cohort was small, these data are different from profiles in younger individuals at early time points post-immunisation and suggest that pneumococcal conjugate vaccines may not quantitatively enhance the generation of memory responses in the elderly.

Original language	English
Pages (from-to)	4763-4770
Number of pages	8
Journal	Vaccine
Volume	28
Issue number	30
DOIs	https://doi.org/10.1016/j.vaccine.2010.04.103
Publication status	Published - Jul 2010

Bibliographical note

Funding Information:
Sources of support: This study was funded by Meningitis UK , the Health Protection Agency UK , the Special Trustees of Great Ormond St and GlaxoSmithKline and the Department of Health (039/031, 3).

Funding Information:
Disclosure: This study was funded in part by an unrestricted grant from GlaxoSmithKline .

Funding Information:
Potential conflicts of interest: D.G. has received honoraria in the past for attendance at advisory boards for Wyeth Pharmaceuticals and receives academic grant support from Merck, Sharpe, and Dohme. All other authors have no conflicts of interest.

Keywords

7vCRM
Aged
B cell memory
ELISpot
Immunogenicity
PPV
Pneumococcus
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2010.04.103

Cite this

@article{12426180e747402a883426554b00c69c,

title = "The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly",

abstract = "In young children, polyvalent pneumococcal polysaccharide conjugate vaccines (PCVs) have been shown to offer advantage over plain polysaccharide vaccines (PPVs) in both immunogenicity and priming for memory responses. In the elderly, the potential benefit of conjugate vaccines is unclear.Here, we explore the early kinetics of serum antibody and circulating plasma and memory B cell responses to pneumococcal capsular polysaccharide (PPS) in older adults (n=37) immunised a PPV vaccine, Pneumovax{\texttrademark} or a PCV: Prevenar{\texttrademark}. All individuals had serum evidence of pre-existing serotype-specific immunity. Following immunisation, a day 7 rise in circulating PPS-specific plasma and memory antibody secreting cells (AbSCs) was detected in both vaccine groups and this was sustained to day 28 in some PCV recipients. There was no difference between vaccine groups in serum antibody responses or the kinetics of the early PBMC-derived B cell responses. Although our sample cohort was small, these data are different from profiles in younger individuals at early time points post-immunisation and suggest that pneumococcal conjugate vaccines may not quantitatively enhance the generation of memory responses in the elderly.",

keywords = "7vCRM, Aged, B cell memory, ELISpot, Immunogenicity, PPV, Pneumococcus, Vaccine",

author = "Baxendale, \{Helen E.\} and Keating, \{Sheila M.\} and Marina Johnson and Jo Southern and Elizabeth Miller and David Goldblatt",

note = "Funding Information: Sources of support: This study was funded by Meningitis UK , the Health Protection Agency UK , the Special Trustees of Great Ormond St and GlaxoSmithKline and the Department of Health (039/031, 3). Funding Information: Disclosure: This study was funded in part by an unrestricted grant from GlaxoSmithKline . Funding Information: Potential conflicts of interest: D.G. has received honoraria in the past for attendance at advisory boards for Wyeth Pharmaceuticals and receives academic grant support from Merck, Sharpe, and Dohme. All other authors have no conflicts of interest.",

year = "2010",

month = jul,

doi = "10.1016/j.vaccine.2010.04.103",

language = "English",

volume = "28",

pages = "4763--4770",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "30",

}

TY - JOUR

T1 - The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly

AU - Baxendale, Helen E.

AU - Keating, Sheila M.

AU - Johnson, Marina

AU - Southern, Jo

AU - Miller, Elizabeth

AU - Goldblatt, David

N1 - Funding Information: Sources of support: This study was funded by Meningitis UK , the Health Protection Agency UK , the Special Trustees of Great Ormond St and GlaxoSmithKline and the Department of Health (039/031, 3). Funding Information: Disclosure: This study was funded in part by an unrestricted grant from GlaxoSmithKline . Funding Information: Potential conflicts of interest: D.G. has received honoraria in the past for attendance at advisory boards for Wyeth Pharmaceuticals and receives academic grant support from Merck, Sharpe, and Dohme. All other authors have no conflicts of interest.

PY - 2010/7

Y1 - 2010/7

N2 - In young children, polyvalent pneumococcal polysaccharide conjugate vaccines (PCVs) have been shown to offer advantage over plain polysaccharide vaccines (PPVs) in both immunogenicity and priming for memory responses. In the elderly, the potential benefit of conjugate vaccines is unclear.Here, we explore the early kinetics of serum antibody and circulating plasma and memory B cell responses to pneumococcal capsular polysaccharide (PPS) in older adults (n=37) immunised a PPV vaccine, Pneumovax™ or a PCV: Prevenar™. All individuals had serum evidence of pre-existing serotype-specific immunity. Following immunisation, a day 7 rise in circulating PPS-specific plasma and memory antibody secreting cells (AbSCs) was detected in both vaccine groups and this was sustained to day 28 in some PCV recipients. There was no difference between vaccine groups in serum antibody responses or the kinetics of the early PBMC-derived B cell responses. Although our sample cohort was small, these data are different from profiles in younger individuals at early time points post-immunisation and suggest that pneumococcal conjugate vaccines may not quantitatively enhance the generation of memory responses in the elderly.

AB - In young children, polyvalent pneumococcal polysaccharide conjugate vaccines (PCVs) have been shown to offer advantage over plain polysaccharide vaccines (PPVs) in both immunogenicity and priming for memory responses. In the elderly, the potential benefit of conjugate vaccines is unclear.Here, we explore the early kinetics of serum antibody and circulating plasma and memory B cell responses to pneumococcal capsular polysaccharide (PPS) in older adults (n=37) immunised a PPV vaccine, Pneumovax™ or a PCV: Prevenar™. All individuals had serum evidence of pre-existing serotype-specific immunity. Following immunisation, a day 7 rise in circulating PPS-specific plasma and memory antibody secreting cells (AbSCs) was detected in both vaccine groups and this was sustained to day 28 in some PCV recipients. There was no difference between vaccine groups in serum antibody responses or the kinetics of the early PBMC-derived B cell responses. Although our sample cohort was small, these data are different from profiles in younger individuals at early time points post-immunisation and suggest that pneumococcal conjugate vaccines may not quantitatively enhance the generation of memory responses in the elderly.

KW - 7vCRM

KW - Aged

KW - B cell memory

KW - ELISpot

KW - Immunogenicity

KW - PPV

KW - Pneumococcus

KW - Vaccine

UR - https://www.scopus.com/pages/publications/77954213676

U2 - 10.1016/j.vaccine.2010.04.103

DO - 10.1016/j.vaccine.2010.04.103

M3 - Article

C2 - 20471437

AN - SCOPUS:77954213676

SN - 0264-410X

VL - 28

SP - 4763

EP - 4770

JO - Vaccine

JF - Vaccine

IS - 30

ER -

The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this